BioStock: Bayer acquires gene therapy company AskBio in billion-dollar deal
The pace of development in gene therapies has accelerated; new treatments are on the way and the interest from investors and the life science sector has certainly not diminished. The area has now received further attention with Bayer’s acquisition of Asklepios BioPharmaceuticals, which was announced on Monday. The purchase price amounted to two billion USD and another two billion when agreed milestones are reached.
Read the full article on the gene therapy deal at biostock.se:
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/